Trials / Completed
CompletedNCT00388531
Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma
Multicenter, Prospective, Open Label Trial, Uncontrolled to Determine the Efficacy and Safety of Depocyt ® for the Treatment of CNS Relapse in Adult Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- PETHEMA Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The first purpose is to confirm or not the efficacy of only one administration of DepoCyte®.
Detailed description
It is a clinical study multicenter, prospective, open label trial, uncontrolled and nonrandomized
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Depocyte® | Depocyte® is a cytostatic drug |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2011-03-01
- Completion
- 2011-06-01
- First posted
- 2006-10-17
- Last updated
- 2011-09-19
Locations
9 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00388531. Inclusion in this directory is not an endorsement.